Crocs (NASDAQ:CROX) Price Target Increased to $34.00 by Analysts at Piper Jaffray Companies

Share on StockTwits

Crocs (NASDAQ:CROX) had its price target boosted by Piper Jaffray Companies from $32.00 to $34.00 in a report released on Tuesday, BenzingaRatingsTable reports. Piper Jaffray Companies currently has an overweight rating on the textile maker’s stock. Piper Jaffray Companies also issued estimates for Crocs’ Q3 2019 earnings at $0.40 EPS, Q4 2019 earnings at $0.07 EPS, FY2019 earnings at $1.42 EPS, Q1 2020 earnings at $0.44 EPS, Q2 2020 earnings at $0.67 EPS, Q4 2020 earnings at $0.13 EPS and FY2020 earnings at $1.72 EPS.

Several other equities research analysts have also recently commented on CROX. Stifel Nicolaus increased their price objective on Crocs from $21.00 to $23.00 and gave the company a hold rating in a research report on Friday, August 2nd. Robert W. Baird raised Crocs from a neutral rating to an outperform rating and set a $29.00 price objective on the stock in a research report on Friday, June 21st. Susquehanna Bancshares increased their price objective on Crocs from $35.00 to $38.00 and gave the company a positive rating in a research report on Friday, August 2nd. Zacks Investment Research raised their target price on Crocs to $32.00 in a research report on Wednesday, September 18th. Finally, ValuEngine cut Crocs from a hold rating to a sell rating in a research report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $31.86.

Crocs stock opened at $30.86 on Tuesday. The company has a debt-to-equity ratio of 3.03, a current ratio of 1.74 and a quick ratio of 1.22. Crocs has a one year low of $17.52 and a one year high of $31.88. The stock has a market capitalization of $2.12 billion, a PE ratio of 34.65 and a beta of 0.96. The business’s fifty day moving average is $26.44 and its 200 day moving average is $24.01.

Crocs (NASDAQ:CROX) last released its quarterly earnings data on Thursday, August 1st. The textile maker reported $0.55 EPS for the quarter, beating the consensus estimate of $0.48 by $0.07. Crocs had a return on equity of 47.15% and a net margin of 5.61%. The company had revenue of $358.90 million for the quarter, compared to analysts’ expectations of $360.46 million. During the same period last year, the firm posted $0.35 earnings per share. Crocs’s revenue was up 9.4% compared to the same quarter last year. As a group, sell-side analysts expect that Crocs will post 1.44 EPS for the current fiscal year.

In other Crocs news, Director Doreen A. Wright sold 7,068 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $26.00, for a total value of $183,768.00. Following the transaction, the director now directly owns 55,680 shares of the company’s stock, valued at $1,447,680. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.42% of the company’s stock.

A number of large investors have recently made changes to their positions in CROX. Marshall Wace LLP boosted its position in Crocs by 95.0% in the first quarter. Marshall Wace LLP now owns 1,739,464 shares of the textile maker’s stock worth $44,790,000 after purchasing an additional 847,515 shares during the last quarter. Copper Rock Capital Partners LLC purchased a new position in Crocs in the third quarter worth about $17,188,000. Morgan Stanley boosted its position in Crocs by 911.1% in the second quarter. Morgan Stanley now owns 612,905 shares of the textile maker’s stock worth $12,105,000 after purchasing an additional 552,290 shares during the last quarter. Renaissance Technologies LLC boosted its position in Crocs by 15.4% in the second quarter. Renaissance Technologies LLC now owns 3,855,300 shares of the textile maker’s stock worth $76,142,000 after purchasing an additional 513,900 shares during the last quarter. Finally, Nuveen Asset Management LLC bought a new position in shares of Crocs in the second quarter worth about $7,426,000.

About Crocs

Crocs, Inc, together with its subsidiaries, designs, develops, manufactures, markets, and distributes casual lifestyle footwear and accessories for men, women, and children worldwide. It offers various footwear products, including clogs, sandals, flips and slides, shoes, and boots under the Crocs brand name.

Featured Article: What is diluted earnings per share (Diluted EPS)?

Analyst Recommendations for Crocs (NASDAQ:CROX)

Receive News & Ratings for Crocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crocs and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Tripadvisor  Rating Reiterated by SunTrust Banks
Tripadvisor Rating Reiterated by SunTrust Banks
Crocs  Price Target Increased to $34.00 by Analysts at Piper Jaffray Companies
Crocs Price Target Increased to $34.00 by Analysts at Piper Jaffray Companies
Hyatt Hotels  PT Set at $70.00 by Cowen
Hyatt Hotels PT Set at $70.00 by Cowen
Zacks: Equinox Gold Cp  Receives Consensus Recommendation of “Buy” from Brokerages
Zacks: Equinox Gold Cp Receives Consensus Recommendation of “Buy” from Brokerages
Nuveen Short Duration Credit Opp Fund  Stock Price Passes Above 50-Day Moving Average of $15.05
Nuveen Short Duration Credit Opp Fund Stock Price Passes Above 50-Day Moving Average of $15.05
Coherus Biosciences  Upgraded at Zacks Investment Research
Coherus Biosciences Upgraded at Zacks Investment Research


 
© 2006-2019 Zolmax.